GlaxoSmithKline Pharmaceuticals Limited

NSEI:GLAXO Stock Report

Market Cap: ₹479.0b

GlaxoSmithKline Pharmaceuticals Future Growth

Future criteria checks 2/6

GlaxoSmithKline Pharmaceuticals is forecast to grow earnings and revenue by 11.8% and 7.5% per annum respectively. EPS is expected to grow by 11.8% per annum. Return on equity is forecast to be 42.4% in 3 years.

Key information

11.8%

Earnings growth rate

11.84%

EPS growth rate

Pharmaceuticals earnings growth14.9%
Revenue growth rate7.5%
Future return on equity42.40%
Analyst coverage

Low

Last updated14 May 2025

Recent future growth updates

Earnings Update: Here's Why Analysts Just Lifted Their GlaxoSmithKline Pharmaceuticals Limited (NSE:GLAXO) Price Target To ₹3,072

May 16
Earnings Update: Here's Why Analysts Just Lifted Their GlaxoSmithKline Pharmaceuticals Limited (NSE:GLAXO) Price Target To ₹3,072

GlaxoSmithKline Pharmaceuticals Limited Just Recorded A 8.7% Revenue Beat: Here's What Analysts Think

Feb 19
GlaxoSmithKline Pharmaceuticals Limited Just Recorded A 8.7% Revenue Beat: Here's What Analysts Think

GlaxoSmithKline Pharmaceuticals Limited (NSE:GLAXO) Just Released Its Second-Quarter Results And Analysts Are Updating Their Estimates

Nov 01
GlaxoSmithKline Pharmaceuticals Limited (NSE:GLAXO) Just Released Its Second-Quarter Results And Analysts Are Updating Their Estimates

The GlaxoSmithKline Pharmaceuticals Limited (NSE:GLAXO) First-Quarter Results Are Out And Analysts Have Published New Forecasts

Aug 05
The GlaxoSmithKline Pharmaceuticals Limited (NSE:GLAXO) First-Quarter Results Are Out And Analysts Have Published New Forecasts

Recent updates

Earnings Update: Here's Why Analysts Just Lifted Their GlaxoSmithKline Pharmaceuticals Limited (NSE:GLAXO) Price Target To ₹3,072

May 16
Earnings Update: Here's Why Analysts Just Lifted Their GlaxoSmithKline Pharmaceuticals Limited (NSE:GLAXO) Price Target To ₹3,072

Earnings Not Telling The Story For GlaxoSmithKline Pharmaceuticals Limited (NSE:GLAXO) After Shares Rise 25%

Mar 13
Earnings Not Telling The Story For GlaxoSmithKline Pharmaceuticals Limited (NSE:GLAXO) After Shares Rise 25%

GlaxoSmithKline Pharmaceuticals Limited Just Recorded A 8.7% Revenue Beat: Here's What Analysts Think

Feb 19
GlaxoSmithKline Pharmaceuticals Limited Just Recorded A 8.7% Revenue Beat: Here's What Analysts Think

Subdued Growth No Barrier To GlaxoSmithKline Pharmaceuticals Limited's (NSE:GLAXO) Price

Jan 22
Subdued Growth No Barrier To GlaxoSmithKline Pharmaceuticals Limited's (NSE:GLAXO) Price

GlaxoSmithKline Pharmaceuticals Limited (NSE:GLAXO) Just Released Its Second-Quarter Results And Analysts Are Updating Their Estimates

Nov 01
GlaxoSmithKline Pharmaceuticals Limited (NSE:GLAXO) Just Released Its Second-Quarter Results And Analysts Are Updating Their Estimates

We Think GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Can Manage Its Debt With Ease

Aug 29
We Think GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Can Manage Its Debt With Ease

The GlaxoSmithKline Pharmaceuticals Limited (NSE:GLAXO) First-Quarter Results Are Out And Analysts Have Published New Forecasts

Aug 05
The GlaxoSmithKline Pharmaceuticals Limited (NSE:GLAXO) First-Quarter Results Are Out And Analysts Have Published New Forecasts

Investors Appear Satisfied With GlaxoSmithKline Pharmaceuticals Limited's (NSE:GLAXO) Prospects As Shares Rocket 26%

Jun 01
Investors Appear Satisfied With GlaxoSmithKline Pharmaceuticals Limited's (NSE:GLAXO) Prospects As Shares Rocket 26%

Earnings and Revenue Growth Forecasts

NSEI:GLAXO - Analysts future estimates and past financials data (INR Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
3/31/202745,25111,75412,52312,6954
3/31/202641,08410,39910,9688,5714
3/31/202538,9519,27612,66912,899N/A
12/31/202437,0468,592N/AN/AN/A
9/30/202435,6056,7509,4019,713N/A
6/30/202435,0676,400N/AN/AN/A
3/31/202434,5375,9005,5085,820N/A
12/31/202333,1145,289N/AN/AN/A
9/30/202333,0846,4786,4496,890N/A
6/30/202332,6836,237N/AN/AN/A
3/31/202332,5176,0764,4024,842N/A
12/31/202232,7394,195N/AN/AN/A
9/30/202232,8753,9403,7864,133N/A
6/30/202233,0483,897N/AN/AN/A
3/31/202232,7803,8087,7618,107N/A
12/31/202134,8615,100N/AN/AN/A
9/30/202134,7084,9627,9128,354N/A
6/30/202133,4033,684N/AN/AN/A
3/31/202129,2562,8735,3375,779N/A
12/31/202031,6094,819N/AN/AN/A
9/30/202030,823-3,3583,8605,419N/A
6/30/202030,850905N/AN/AN/A
3/31/202032,2449323,3464,905N/A
12/31/201931,9941,019N/AN/AN/A
9/30/201932,4618,7682,8455,758N/A
6/30/201931,8044,749N/AN/AN/A
3/31/201931,2814,4541,1824,095N/A
3/31/201828,7153,507N/A4,728N/A
3/31/201729,0853,368N/A2,344N/A
3/31/201628,3793,761N/A1,389N/A
3/31/201526,3843,811N/A2,701N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: GLAXO's forecast earnings growth (11.8% per year) is above the savings rate (6.7%).

Earnings vs Market: GLAXO's earnings (11.8% per year) are forecast to grow slower than the Indian market (15.6% per year).

High Growth Earnings: GLAXO's earnings are forecast to grow, but not significantly.

Revenue vs Market: GLAXO's revenue (7.5% per year) is forecast to grow slower than the Indian market (9.4% per year).

High Growth Revenue: GLAXO's revenue (7.5% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: GLAXO's Return on Equity is forecast to be very high in 3 years time (42.4%).

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/05/18 06:11
End of Day Share Price 2025/05/16 00:00
Earnings2025/03/31
Annual Earnings2025/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

GlaxoSmithKline Pharmaceuticals Limited is covered by 24 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Shirish PardeshiAnand Rathi Shares and Stock Brokers Limited
Sarabjit NangraAngel Broking Private Limited
Prakash AgarwalAxis Capital Limited